What are the different types of pancreatic tumors, their clinical presentation, diagnostic work‑up, staging, and treatment options?

Pancreatic Tumors: Comprehensive Overview

Types of Pancreatic Tumors

Pancreatic ductal adenocarcinoma (PDAC) represents approximately 80% of all pancreatic cancers and is the most lethal form, while neuroendocrine tumors account for the second most common type at roughly 2% of cases 1, 2.

Exocrine Tumors (95% of pancreatic tumors)

• Pancreatic ductal adenocarcinoma (PDAC): 70-95% of all solid pancreatic neoplasms, arising from ductal epithelium with characteristic intense stromal reaction 1, 2
• Adenosquamous carcinoma: Associated with poorer prognosis than PDAC 1
• Acinar cell carcinoma: Slightly better prognosis than PDAC 1
• Cystic neoplasms (10-15% of cystic lesions): Include serous cystadenoma, intraductal papillary mucinous neoplasm (IPMN), and mucinous cystic neoplasm with malignant potential 1
• Solid pseudopapillary tumor: Less common variant 2

Endocrine Tumors (2% of pancreatic tumors)

• Pancreatic neuroendocrine tumors (pNETs): Classified by WHO 2010 as NET G1 (Ki-67 ≤2%), NET G2 (Ki-67 3-20%), or NEC G3 (Ki-67 >20%) 1
• Functioning tumors (40-55% of pNETs): Insulinoma, gastrinoma, glucagonoma, VIPoma 1
• Non-functioning tumors (45-60% of pNETs): May secrete chromogranin A or pancreatic polypeptide 1

Clinical Presentation

PDAC Presentation

• Jaundice: Present in 70-80% of pancreatic head tumors due to biliary obstruction 1
• Abdominal pain: Common presenting symptom, often radiating to the back
• Weight loss: Frequently accompanies advanced disease
• Duodenal obstruction: Less than 5% at presentation, more common during disease progression 1
• New-onset diabetes: Can precede diagnosis in some patients

pNET Presentation

• Carcinoid syndrome (30% of small intestinal NETs): Flushing, diarrhea, endocardial fibrosis, wheezing from serotonin release by liver metastases 1
• Hormone-specific symptoms: Hypoglycemia (insulinoma), Zollinger-Ellison syndrome (gastrinoma), glucagonoma syndrome, Verner-Morrison syndrome (VIPoma) 1
• Non-functioning tumors: Often asymptomatic until mass effect or metastases occur 1

Diagnostic Work-Up

Imaging Protocol

Multi-detector CT (MD-CT) with specialized pancreatic protocol is the preferred initial imaging modality, requiring triphasic cross-sectional imaging with thin 3mm slices through arterial, pancreatic parenchymal, and portal venous phases 1.

• CT scan sensitivity: 76-92% for pancreatic cancer diagnosis 2
• MRI plus MRCP: Alternative to CT with 90-100% accuracy for detection and staging, particularly useful for patients requiring contrast alternatives 1, 2
• Endoscopic ultrasound (EUS): 98% sensitivity for pancreatic lesions, most sensitive for tumors <2cm, provides vessel invasion assessment and lymph node evaluation 1, 2
• Chest MD-CT: Mandatory to evaluate potential lung metastases 1

Advanced Imaging

• PET-CT: Can be considered for staging in non-metastatic disease when local treatment (surgery/radiotherapy) is planned, but not routinely recommended for ductal pancreatic cancer staging 1
• Laparoscopy: Detects small peritoneal and liver metastases in <15% of patients, performed before resection in left-sided large tumors, high CA19.9 levels, or when neoadjuvant treatment is considered 1
• For pNETs: Somatostatin receptor scintigraphy complemented by CT/MRI; PET scanning with 11C-5HTP, 18F-DOPA, or 18F-DG can optimize staging 1

Tissue Diagnosis

For patients undergoing surgery with radical intent, pre-operative biopsy is not obligatory; biopsy should be restricted to cases where imaging is ambiguous or chemotherapy will precede surgery 1.

• EUS-guided fine-needle biopsy: Preferred over CT-guided biopsy for resectable disease due to better diagnostic yield, safety, and lower risk of peritoneal seeding 1
• Percutaneous biopsy: Should be avoided for potentially resectable lesions but acceptable for metastatic lesions under ultrasound or CT guidance 1
• Treatment without histology: May proceed after two inconclusive biopsy attempts if multidisciplinary tumor board discussion, imaging, and CA19.9 are consistent with malignancy 1

Biomarkers

• CA19.9: Can guide treatment and follow-up with prognostic value in absence of cholestasis; post-resection levels have confirmed prognostic significance 1
• Chromogranin A (pCgA): General marker for pNETs, often normal in poorly differentiated G3 tumors 1, 3
• Urine 5-HIAA: Important for small intestinal NETs with carcinoid syndrome 1
• Specific hormones: Gastrin, insulin, glucagon, VIP measured based on clinical symptoms for functioning pNETs 1

Staging

The TNM staging system developed by the AJCC-UICC is the established standard for pancreatic cancer 1.

Practical Staging Categories

• Resectable: Cancer localized to pancreas or just beyond, with complete surgical removal possible 1
• Borderline resectable: Larger tumors with vessel encasement that may benefit from neoadjuvant therapy to achieve downsizing and potential conversion to resectable 1
• Locally advanced-unresectable: Extensive involvement of nearby blood vessels or spread beyond pancreas preventing complete surgical removal, without distant organ involvement 1
• Metastatic (Stage IV): Distant organ spread identified 1

Prognostic Factors

• Resection margin status: Negative margins (R0) are critical; microscopic margin involvement occurs in >75% of cases and correlates with survival 1
• Lymph node ratio (LNR): LNR ≥0.2 (involved/examined lymph nodes) is a negative prognostic factor 1
• Tumor size, nodal involvement, histological grade: Strong prognostic factors 1
• Genetic mutations: KRAS (>90%), TP53, p16/CDKN2A, SMAD4 inactivation; HRR pathway alterations (BRCA1/BRCA2) have therapeutic implications 1

Treatment Options

Resectable Disease (Stage I and Some Stage II)

Radical surgery is the only curative treatment for pancreatic cancer, primarily suitable for early-stage disease 1.

Surgical Procedures

• Pancreatic head tumors: Partial pancreaticoduodenectomy (Whipple procedure or pylorus-preserving variant) is the treatment of choice 1
• Body/tail tumors: Distal pancreatectomy with splenectomy 1
• Total pancreatectomy: Required in select cases 1
• Lymphadenectomy: Standard (not extended) lymphadenectomy includes hepatoduodenal ligament, common hepatic artery, portal vein, right-sided celiac artery, and right half of superior mesenteric artery nodes 1
• Elderly patients: Benefit from radical surgery, but comorbidity may preclude resection, especially in patients >75-80 years 1

Adjuvant Therapy

Postoperatively, 6 months of gemcitabine (GEM) or 5-fluorouracil (5-FU) chemotherapy are recommended 1.

• R1 resection: Patients benefit from adjuvant/additive chemotherapy even after incomplete resection 1
• Chemoradiation: Should only be performed within randomized controlled clinical trials in the adjuvant setting 1
• 5-FU-based chemoradiation: May be considered following GEM chemotherapy (RTOG 97-04 protocol) for pancreatic head tumors, large diameter (>3cm), or R1 resection 1

Borderline Resectable Disease

Patients with larger tumors and/or vessel encasement may benefit from neoadjuvant chemotherapy or chemoradiotherapy to achieve tumor downsizing and conversion to resectable status 1.

• Neoadjuvant approach: Should be performed within clinical trials for resectable disease; useful for borderline cases 1
• Contraindication to surgery: Patients developing metastases during neoadjuvant therapy or with local progression are not surgical candidates 1

Locally Advanced Unresectable Disease (Stage IIB and III)

• 5-FU chemoradiation: Can be considered, though recent trials show contradictory results 1
• Selective chemoradiation: Patients treated with GEM who do not progress after 3 months with good performance status may benefit from added chemoradiation 1
• Palliative bypass: For intestinal obstruction followed by chemotherapy or chemoradiation 1

Metastatic Disease (Stage IV)

For patients with metastatic disease and good performance status (≤75 years, PS 0-1, bilirubin ≤1.5 ULN), FOLFIRINOX protocol confers significant improvement in overall survival and represents a novel therapeutic option 1.

First-Line Chemotherapy

• Gemcitabine monotherapy: Conventional dosing (1000 mg/m² over 30 minutes) is recommended for unresectable tumors and was standard until recently 1
• FOLFIRINOX: Significant survival advantage in stage IV disease for selected patients 1
• GEM plus erlotinib: Can be used, but erlotinib continued only if skin rash develops within first 8 weeks 1
• GEM combinations: With 5-FU, capecitabine, irinotecan, or platinum agents do not confer significant survival advantage and should not be used as standard first-line treatment 1

Second-Line Chemotherapy

• 5-FU plus oxaliplatin: Treatment option after first-line GEM progression 1
• Gemcitabine: Can be considered after first-line FOLFIRINOX progression 1

Palliative Therapy

Endoscopic stenting is the preferred procedure for biliary obstruction in unresectable patients 1.

• Metal prostheses: Preferred for patients with life expectancy >3 months due to fewer complications than plastic stents 1
• Plastic stents: Should be replaced at least every 6 months to avoid occlusion and ascending cholangitis 1
• Percutaneous approach: When endoscopic treatment is not possible 1

Neuroendocrine Tumors

• Surgical resection: Only curative option for localized pNETs; debulking operations effective for disease control 3
• First-line therapy: Somatostatin analogues for somatostatin receptor-positive tumors 3
• Advanced disease: Everolimus and sunitinib represent important progress for advanced pNETs 3
• 5-year survival: Metastatic carcinoid tumors ~75% in dedicated centers; metastatic pancreatic NETs >60% 1

Key Clinical Pitfalls

• Avoid percutaneous biopsy of potentially resectable pancreatic lesions due to risk of peritoneal seeding; use EUS-guided approach instead 1
• Do not delay surgery for non-diagnostic biopsy when clinical suspicion for pancreatic cancer is high 1
• Refer to high-volume centers: Resections should be performed at institutions conducting 15-20 pancreatic resections annually 1
• Standardized pathology reporting: Critical for assessing margins and providing prognostic data; LNR should always be indicated 1
• Positive peritoneal washings: Equivalent to M1 disease; if resection performed, treat as metastatic disease 1
• Bone scan not useful: Only few patients present with bone involvement at diagnosis 1
• Intraoperative radiotherapy: Remains experimental and cannot be recommended for routine use 1